Last week IBM signed a memorandum of understanding with Skolkovo, the international tech hub under completion on the outskirts of Moscow, the First Oncology Research and Advisory Center (FORAC), a resident of Skolkovo’s biomedical cluster. The three partner will develop a personalized medical platform in Russia in a joint strategic, technology and commercial collaboration effort.
The platform will feature advanced solutions to support clinical decisions. Made available to oncology researchers, clinics and institutions, it will “help doctors narrow down all available cancer trials and quickly identify potential matches, offering promising new approaches and treatment options to extend the healthy productive lives of patients with cancer and other age-related diseases.”
The platform will be supported by IBM’s Watson Health and FORAC’s OncoFinder solution.
“The OncoFinder is a popular signalome-wide pathway analysis platform used for personalizedmedicine and drug repurposing. Combined with IBM Watson, which is likely the world’s most powerful decision support system capable of bringing research and precision to medicine, this could help save lives, optimize health care and accelerate the pace of clinical research,” explained Anton Buzdin, PhD, DSc, CEO of FORAC.
Powered by Watson’s cognitive computing capabilities, IBM Watson Health is capable of “dramatically improving the ability of doctors, researchers and insurers to surface new insights from the large amounts of personal health data being created daily.”
“The cooperation with First Oncology Research and Advisory Center and Skolkovo will further support IBM’s mission of using powerful cognitive computing to underpin a new, personalized and holistic approach to healthcare,” said an IBM representative.
The agreement was signed during the St. Petersburg International Economic Forum by Victor Vekselberg, President of the Skolkovo Foundation, Anton Buzdin, PhD, DSc, CEO of FORAC, and Kirill Korniliev, General Manager at IBM Russia and CIS.
Source: Skolkovo Foundation
